Applications of D-Ornithine Monohydrochloride in Industrial Manufacturing

D-Ornithine Monohydrochloride is a specialty amino acid compound with well-established downstream roles across several industrial sectors. As an original manufacturer, we supply this material to clients who demand reliable performance and consistent specification for use in tightly regulated applications. The following scenarios detail actual integration points, industry compliance frameworks, formulation guidelines, downstream processing stages, and representative final product types observed among our client base and verified global market users.

1. Pharmaceutical API Synthesis

Pharmaceutical firms employ D-Ornithine Monohydrochloride as a chiral building block in peptide drug synthesis, particularly in formulations where precise stereochemistry is critical for therapeutic effect. Its role in solid-phase peptide synthesis (SPPS) and solution-phase processes facilitates the assembly of targeted bioactive compounds—commonly in therapeutics for metabolic disorders and neuromodulation. Manufacturers submit these products for rigorous regulatory review prior to market entry, ensuring batch-to-batch consistency and traceability from raw material to active pharmaceutical ingredient (API).

Industry compliance standards

• Current Good Manufacturing Practice (cGMP): ICH Q7, FDA 21 CFR Part 210/211, EU GMP
• Pharmacopoeias: United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), Japanese Pharmacopoeia (JP)
• Regulatory submissions: Drug Master File (DMF, Type II), Certificate of Suitability (CEP)
• Quality management: ISO 9001, ISO 13485 (if used in medical device components)

Typical usage ratio

• 1-15 mol% relative to peptide chain length for SPPS; varies with peptide complexity and scale
• Process development teams may adjust amounts based on peptide sequence, solubility, and downstream functionalization requirements

Downstream process integration

• Entry during amino acid coupling cycles in automated or batch-mode syntheses
• Pre-purification via preparative HPLC or crystallization, depending on impurity profile
• Documentation for traceability is attached at incoming QC and transfer to API manufacturing

Final product types

• Injectable or oral peptide APIs for metabolic and neurological therapies
• Intermediate compounds for use in further drug discovery or custom peptide libraries
• Chemically defined reference standards for pharmaceutical analysis laboratories

2. Nutritional Supplement Manufacturing

Producers of amino acid-based food supplements utilize D-Ornithine Monohydrochloride for formulations supporting dietary protein metabolism and sports nutrition. Its enantiomeric purity and solubility offer reliable integration into granulated blends, direct-compression tablets, and sachet premixes. All processing and material handling require demonstration of safety and absence of prohibited impurities, especially for products registered in developed markets.

Industry compliance standards

• FSMA (U.S. Food Safety Modernization Act) and FDA 21 CFR Part 111 (Dietary Supplement GMP)
• Codex Alimentarius, EC Regulation 1924/2006 (nutrition and health claims)
• Prop 65 (California), Where applicable for contaminants
• ISO 22000 food safety management

Typical usage ratio

• 100–800 mg per daily serving in finished supplement, adjusted per regional limits and formulation
• 0.2–2% mass/mass in direct-compression blends or powder premixes

Downstream process integration

• Blending with micronutrients or other amino acids in rotary batch mixers
• Dry granulation or drum pelletization for tablet manufacturing
• Quality control: Identity, purity, and heavy metal screenings post-blending

Final product types

• Tablets and capsules labeled as nutritional amino acid supplements
• Single-serve sport nutrition sachets or effervescent powders
• Fortified protein shakes and clinical dietary blends

3. Diagnostic Reagent and In Vitro Diagnostic (IVD) Kit Production

Manufacturers of clinical chemistry and research diagnostic reagents incorporate D-Ornithine Monohydrochloride as a substrate or standard, especially in enzyme activity assays such as those for ornithine transcarbamylase or arginase disorders. The purity and lot reproducibility are essential to minimize background noise and ensure reliable analytic performance. Batch traceability and comprehensive documentation support audit and batch release requirements for regulated markets.

Industry compliance standards

• ISO 13485: Medical Devices – Quality Management Systems
• IVDR (EU Regulation 2017/746 on in vitro diagnostic medical devices)
• FDA 21 CFR Part 820 (QSR for medical device manufacturers)
• CLSI (Clinical and Laboratory Standards Institute) guidelines

Typical usage ratio

• 1–15 mM final concentration in prepared buffer solutions for kit vials
• 5–250 µg per assay, depending on substrate concentration requirements

Downstream process integration

• Weighing and dissolution into buffer formulations under cleanroom conditions
• Auto-dispensing into single-use vials or sealed multi-well plates
• Sterile filtration before packaging for diagnostic product stability

Final product types

• Clinical chemistry test kits for urea cycle and liver function studies
• Enzymatic substrate kits for use in automated analyzers
• Research-use-only (RUO) biochemical assay reagents

4. Cell Culture Medium and Bioprocessing Additive

Biotechnology and pharmaceutical production facilities source D-Ornithine Monohydrochloride for inclusion in defined cell culture media formulations. The amino acid provides critical nutritional or metabolic support in select mammalian cell lines, including in monoclonal antibody and recombinant protein production. Consistent supply and validated impurity profiles protect downstream batches from toxicity and variability during cell expansion.

Industry compliance standards

• USP Chapter <1043> Ancillary Materials for Cell, Gene, and Tissue-Engineered Products
• GMP for biological production (FDA 21 CFR 600-680, EudraLex Volume 4: GMP for Advanced Therapy Medicinal Products)
• ISO 9001 quality systems for biological raw materials
• TSE/BSE risk assessment, certificate of origin

Typical usage ratio

• 0.01–0.1 g/L in custom-defined media; adjustments based on clone requirements and experimental scale
• Supplementation may be batch-specific, linked to process optimization results

Downstream process integration

• Sterile addition to basal media during media preparation or immediately prior to inoculation
• Integration in fed-batch or perfusion protocol feeds, monitored via inline analytics
• QC verification at raw material receipt and after final media filtration

Final product types

• Recombinant biotherapeutic proteins
• Monoclonal antibody drug substances
• Custom cell growth media concentrates and media kits